AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12499335
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of supplement
Trial: 2003341
Drug: Trimethoprim and
RxNorm normalized name: Trimethoprim and derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim and sulfamethoxazole (TMP/SMX) taken orally twice a day for seven days
Trial: 6663617
Drug: Lens-implant or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lens-implant or contact-lens correction
Trial: 28942334
Drug: 25-μg rhPTH(1‐84)
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-μg rhPTH(1‐84) daily dose
Trial: 28942334
Drug: 50-μg rhPTH(1‐84)
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-μg rhPTH(1‐84) daily dose
Trial: 17468682
Drug: Efficacious treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacious treatment
Trial: 11305822
Drug: Flurbiprofen 1
RxNorm normalized name: flurbiprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 1 mg x kg(‐1) iv 30 min before surgery (PRE)
Trial: 11305822
Drug: Flurbiprofen 1
RxNorm normalized name: flurbiprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 1 mg x kg(‐1) iv at the end of surgery (POST)
Trial: 3598225
Drug: 100% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% of the standard im dose of HDCV
Trial: 3598225
Drug: 10% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% of the standard im dose of HDCV
Trial: 3598225
Drug: 3% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% of the standard im dose of HDCV
Trial: 3598225
Drug: 10% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% of the standard im dose id of HDCV
Trial: 3598225
Drug: 3% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% of the standard im dose id of HDCV
Trial: 23818758
Drug: Higher-dose inhaled
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose inhaled corticosteroids (ICS) in combination with long-acting beta-agonist (LABA) for one month, then shifted to guideline doses.
Trial: 23818758
Drug: Guideline doses
RxNorm normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline doses (GD) therapy alone.
Trial: 20524439
Drug: Ketotifen (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (0.5 mg or 1 mg orally twice daily)
Trial: 20524439
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 microg inhaled twice daily)
Trial: 16600723
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg daily for 24 months
Trial: 12677572
Drug: TMP/SMZ (TMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMZ (TMP 4 mg/kg/d and SMZ 20 mg/kg/d, divided in 2 doses)
Trial: 12677572
Drug: Neomycin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin (25 mg/kg/d, qid, 4 days a week)
Trial: 8373610
Drug: PGE1 (0.11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (0.11 +/- 0.03 micrograms/kg/min) infusion
Trial: 27426276
Drug: Pramipexole (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (titrated from 0.09 to 0.54 mg, o.d., for 3 weeks)
Trial: 17216435
Drug: Mefloquine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (250 mg base daily for 3 days, then 250 mg weekly for 6 months)
Trial: 15161780
Drug: Multifaceted provider-level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted provider-level intervention (six monthly visits by a multidisciplinary health care team)
Trial: 7997385
Drug: Torsemide 5
RxNorm normalized name: torsemide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide 5 mg
Trial: 7997385
Drug: Torsemide 10
RxNorm normalized name: torsemide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide 10 mg
Trial: 7997385
Drug: Torsemide 20
RxNorm normalized name: torsemide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide 20 mg
Trial: 30689618
Drug: Light-emitting diode
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-emitting diode therapy (LEDT) applied to biceps brachii after strength training
Trial: 25307829
Drug: Multidisciplinary group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary group-based rehabilitation program with monthly motivational consultation
Trial: 25307829
Drug: Oral drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug treatment alone
Trial: 25715157
Drug: CPS5‐TT/CPS8‐TT/AT/ClfA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPS5‐TT/CPS8‐TT/AT/ClfA vaccine (5/5/10/10 μg or 10/10/30/30 μg dose with or without AS03B adjuvant)
Trial: 21333346
Drug: High-dose maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose maintenance vaccine (4200 allergen units, approximately 70 μg of Der f 1/d)
Trial: 21333346
Drug: Low-dose maintenance
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose maintenance vaccine (60 allergen units, approximately 1 μg of Der f 1/d)
Trial: 14660478
Drug: Ribose (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribose (200 mg/kg body wt; Rib)
Trial: 9822512
Drug: Clindamycin 900
RxNorm normalized name: clindamycin 900 MG in 6 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 900 mg every 8 hours and gentamicin 1.5 mg/kg every 8 hours until afebrile for a minimum of 24 hours (group 2)
Trial: 9822512
Drug: No scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No scheduled postoperative antibiotics (group 1)
Trial: 7853818
Drug: Gastrozepin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrozepin treatment
Trial: 7853818
Drug: Ranisan treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranisan treatment
Trial: 30841744
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy augmented with movement or occupational therapy (n=23)
Trial: 28625506
Drug: lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lixisenatide 20 μg
Trial: 25792607
Drug: Mass isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mass isoniazid preventive therapy for 9 months
Trial: 25792607
Drug: Additional interventions
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional interventions (improving diagnostics, reducing treatment delay, providing continuous isoniazid preventive therapy to HIV-positive people, scaling up antiretroviral treatment coverage)
Trial: 18165596
Drug: IV patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV patient-controlled morphine
Trial: 12590006
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (10 mg/day, n=18)
Trial: 11794823
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (0.625 mg conjugated estrogen/day combined with medroxyprogesterone 5 mg/day)
Trial: 11794823
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy plus pravastatin
Trial: 8683230
Drug: Anastrozole 10
RxNorm normalized name: anastrozole 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 10 mg once daily
Trial: 9740079
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 40 mg 4 times daily
Trial: 2659442
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 3 g amoxicillin (group A)
Trial: 2659442
Drug: 4-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day course of 3 X 750 mg amoxicillin (group B)
Trial: 4613531
Drug: Prostaglandin F2alpha
RxNorm normalized name: Prostaglandin F2alpha tham
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2alpha (PGF2alpha) administered extraamniotically
Trial: 4613531
Drug: Prostaglandin F2alpha
RxNorm normalized name: Prostaglandin F2alpha tham
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2alpha (PGF2alpha) administered intraamniotically
Trial: 30464914
Drug: i/v ceftazidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i/v ceftazidine 1 gm bd with oral ciprofloxacin 750 mg bd
Trial: 30464914
Drug: surgical debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surgical debridement with oral ciprofloxacin 750 mg bd
Trial: 26466613
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg od (or 15 mg od in patients with moderate renal insufficiency)
Trial: 26466613
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR target 2.5)
Trial: 17145785
Drug: Crushed voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed voriconazole tablets
Trial: 17145785
Drug: Whole voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Whole voriconazole tablets
Trial: 11993619
Drug: Low rate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low rate of fluid intake (L) - 120% of BW loss ingested at 24% x h(‐1) during 5 hours.
Trial: 7795155
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day beta‐carotene for 14 weeks
Trial: 1693411
Drug: Amoxicillin combined
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin combined with xylometazoline hydrochloride nose drops
Trial: 1693411
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of maxillary sinus drainage and amoxicillin with xylometazoline
Trial: 28234636
Drug: Ropivacaine-based periarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine-based periarticular injection
Trial: 28234636
Drug: Liposomal bupivacaine-based
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine-based periarticular injection
Trial: 25275888
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg·kg(‐1))
Trial: 15339328
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg/q.d.s.
Trial: 15339328
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg/q.d.s.
Trial: 15339328
Drug: Pantoprazole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 10 mg/q.d.s.
Trial: 15339328
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg/b.d.
Trial: 1825037
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of acetylcholine or ergonovine
Trial: 23192720
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (Control)
Trial: 31775837
Drug: Bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus therapy with 20-40 ml/kg 5% albumin or 0.9% saline over 1-2 h
Trial: 31775837
Drug: No bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bolus (control, 4 ml/kg/hour maintenance)
Trial: 8390287
Drug: Bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus therapy
Trial: 29985860
Drug: Telenursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telenursing intervention with weekly follow-up phone calls for 12 weeks and availability of telenurse for calls anytime.
Trial: 26818893
Drug: Insulin initiation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin initiation willingness
Trial: 26818893
Drug: Socioeconomic status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socioeconomic status and insulin appraisals
Trial: 26983672
Drug: Passive physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive physical therapy (Arm B)
Trial: 19190878
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 1g/kg for two consecutive days (total dose 2 g/kg)
Trial: 19190878
Drug: Intravenous anti-D
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anti-D immunoglobulin 75 microg/kg (single dose)
Trial: 16187243
Drug: Pamidronate (treatment)
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate (treatment)
Trial: 9581302
Drug: Cefixime (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (8 mg/kg per day for 5 days)
Trial: 8229498
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX, 10-50 mg/kg per day for 5 days)
Trial: 31199595
Drug: Reconval K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconval K1 cream
Trial: 26994228
Drug: GDHT (goal-directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDHT (goal-directed haemodynamic treatment)
Trial: 26994228
Drug: Routine fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fluid treatment (clinician-guided)
Trial: 24217219
Drug: Cortisol infusion
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol infusion to increase plasma cortisol concentration to a level associated with major physiologic stress.
Trial: 24217219
Drug: Saline pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline pre-treatment (Control group).
Trial: 19567826
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (21 mg/24 hr)
Trial: 12359986
Drug: Dietary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intervention program administered by a dietitian
Trial: 12359986
Drug: Dietary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intervention program administered by a doctor of chiropractic in conjunction with chiropractic spinal manipulation
Trial: 28784536
Drug: Matcha tea
RxNorm normalized name: Matcha Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matcha tea bar (4 g matcha tea powder)
Trial: 21494061
Drug: Wisdom psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wisdom psychotherapy (PTED-specific cognitive behaviour therapy)
Trial: 21494061
Drug: Routine multidimensional
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine multidimensional cognitive behaviour therapy
Trial: 16794200
Drug: Dispersible aspirin
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible aspirin 75 mg
Trial: 16794200
Drug: Enteric-coated 75
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated 75 mg aspirin
Trial: 16794200
Drug: Asasantin (25-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily)
Trial: 16794200
Drug: Other aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Other aspirin preparations (3 different enteric-coated 75 mg aspirins)
Trial: 3295148
Drug: Computer-assisted dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted dosing (Warfcalc)
Trial: 30872375
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg THC
Trial: 11502903
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 300 mg twice daily
Trial: 11502903
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 200 mg three times daily
Trial: 11502903
Drug: Placebo (neither
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (neither treatment)
Trial: 7963729
Drug: HIV subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV subunit vaccine (rgp120SF2) combined with MF59 adjuvant
Trial: 1316584
Drug: Felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (10 mg)
Trial: 25075
Drug: Timolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (10 mg)
Trial: 2442512
Drug: Timolol and
RxNorm normalized name: timolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol and all beta-blocker/felodipine combinations
Trial: 2442512
Drug: Felodipine/beta-blocker combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine/beta-blocker combinations
Trial: 28167477
Drug: Entoban capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entoban capsule 400mg every 8 hours for five days
Trial: 28167477
Drug: Metronidazole tablets
RxNorm normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole tablets (400 mg) for 7‐10 days
Trial: 25758273
Drug: Rosuvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin treatment
Trial: 23547489
Drug: Tongue cleaning
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue cleaning with meridol HALITOSIS tooth & tongue gel (C)
Trial: 23547489
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (A)
Trial: 23379974
Drug: Fidaxomicin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidaxomicin (200 mg twice daily for 10 days)
Trial: 19463375
Drug: CYP2C19*1*1 carriers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19*1*1 carriers after a 600-mg dose
Trial: 19463375
Drug: CYP2C19*2 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19*2 or *4 carriers after a 600-mg dose
Trial: 19463375
Drug: CYP2C19*17 carriers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19*17 carriers after a 600-mg dose
Trial: 19463375
Drug: CYP2C19*2 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19*2 or *4 carriers with higher loading dose at 4 h
Trial: 19463375
Drug: CYP2C19*2 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19*2 or *4 carriers with higher maintenance dose regimen
Trial: 14749149
Drug: BIAsp 30
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIAsp 30 + ROS (biphasic insulin aspart 30 plus rosiglitazone 4 mg once daily)
Trial: 14749149
Drug: GLIB +
RxNorm normalized name: glibornuride
DrugBank: Glibornuride (DB08962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLIB + ROS (glibenclamide plus rosiglitazone 4 mg once daily)
Trial: 10826396
Drug: Doxazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1 to 16 mg/day)
Trial: 8858401
Drug: L-carnitine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (3 g/day for 3 weeks)
Trial: 8858401
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g/day for 3 weeks)
Trial: 24995700
Drug: Selective iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective iron group (elemental iron 50 mg twice a day if diagnosed as anaemic)
Trial: 24995700
Drug: Routine iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine iron group (elemental iron 100 mg day(‐1) throughout pregnancy)
Trial: 22762951
Drug: Peer change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer change agent (PCA) identification and recruitment methodology based on social network analysis.
Trial: 17919489
Drug: HCV-specific CD8
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV-specific CD8 T-cell response before treatment